Ipamorelin was never developed for anti-aging or body composition. Its only published human efficacy trial tested it for postoperative bowel recovery, missed its endpoint, and development was discontinued afterward.
Ipamorelin is a selective growth hormone secretagogue that acts on the ghrelin receptor to trigger a pulse of GH release from the pituitary [1]. It does not act on the GHRH receptor, which is what separates it from sermorelin and CJC-1295. On its own it is a single-pathway stimulus, and most clinical use pairs it with a GHRH analog rather than running it as monotherapy.
- Ipamorelin acts on the ghrelin receptor, a different pathway from the GHRH receptor sermorelin uses [1]
- Its defining feature is selectivity: in animal models it raised GH without raising cortisol or ACTH, unlike older GHRPs [1]
- That selectivity data comes from swine and rats, not humans [1]
- Its only published human efficacy trial was for postoperative ileus and missed its primary endpoint [3]
- An FDA advisory committee voted 0 in favor and 12 against permitting it for compounding [4]
- FDA lists ipamorelin acetate among bulk substances flagged as a safety risk for compounding [5]
What Ipamorelin Is
Ipamorelin is a synthetic pentapeptide and a growth hormone secretagogue. Where a GHRH analog tells the pituitary to release GH through the GHRH receptor, ipamorelin works through the ghrelin receptor, the same receptor the hunger hormone ghrelin binds [1]. Both routes end in a GH pulse. They start in different places, which is the reason the two get combined.
The Selectivity That Made It Preferred
Ipamorelin was introduced as the first selective growth hormone secretagogue [1], and selectivity is why it displaced older peptides like GHRP-6 and GHRP-2. In that work, ipamorelin did not release ACTH or cortisol at levels different from GHRH stimulation even at doses more than 200 times its GH ED50, while GHRP-6 and GHRP-2 raised both.
Two limits belong next to that claim. The study was done in swine and rats, so the cortisol selectivity rests on animal data rather than human measurement [1]. And the frequently repeated prolactin claim is weaker than presented: the paper found none of the secretagogues tested affected prolactin, which makes it a property of the class in that experiment rather than an ipamorelin-specific edge [1].
Older GHRPs that raise cortisol and prolactin can work against the reason someone starts GH-axis therapy. A cortisol rise blunts recovery and sleep. Ipamorelin's appeal is that it delivers the GH pulse without dragging those along, at least in the animal data available [1].
What the Human Evidence Actually Shows
Ipamorelin's clinical development did not target body composition or aging. It was tested for postoperative ileus, the slowdown of bowel function after surgery. The only published efficacy trial found a median time to first tolerated meal of 25.3 hours versus 32.6 hours on placebo, which did not reach statistical significance [3]. Development was discontinued afterward.
That history matters for anyone using it for muscle, fat, or recovery. The uses ipamorelin is now sold for were never the uses it was tested for. There is no published human trial of ipamorelin for body composition, and none testing it combined with sermorelin.
Why It Is Usually Stacked, Not Run Alone
The mechanistic case for pairing ipamorelin with a GHRH analog is real, and it is the strongest evidence in its favor. In normal subjects given GHRH and a secretagogue separately and together, GH area under the curve was 686 for GHRH alone, 1787 for the secretagogue alone, and 4111 for the combination, significantly higher than the arithmetic sum of the two [2]. Two pathways pushed at once produce more GH than either pushed alone.
It tested GHRP-6 with GHRH, not ipamorelin with sermorelin. The principle that a GHRH analog plus a secretagogue is supra-additive is established in humans. That this particular pairing reproduces that exact magnitude is an extrapolation [2].
This is why ipamorelin rarely appears as monotherapy on a considered protocol. Alone it is one lever. Paired with sermorelin or CJC-1295 it becomes the second half of a two-pathway stimulus, which is where the combined-dose rationale comes from.
Regulatory Standing
This is where ipamorelin differs most from sermorelin, and it is rarely disclosed at point of sale. FDA states there are no approved drug products containing ipamorelin in any form, and lists ipamorelin acetate among bulk drug substances for use in compounding that may present significant safety risks [5]. The stated concerns are immunogenicity risk from aggregation or impurities, unnatural amino acids that complicate characterization, and published serious adverse events including death when it was given intravenously for gastric motility.
In October 2024, FDA's Pharmacy Compounding Advisory Committee voted on whether to place ipamorelin on the 503A bulks list. The result was 0 in favor, 12 against, 1 abstention for both the free base and acetate forms [4], with the committee citing a lack of data supporting safety and efficacy.
Ipamorelin is also named explicitly on the 2026 WADA Prohibited List under section S2.2.4 [6], prohibited at all times in and out of competition. Anyone subject to anti-doping testing should treat it as off the table.
The Honest Verdict
Ipamorelin is a genuinely selective secretagogue with a sound mechanistic rationale and a thin human evidence base. The selectivity is real but shown in animals. The stacking logic is real but demonstrated with a different peptide. The regulatory signals are the weakest part of the picture and the least advertised.
For someone considering it, the conservative path is the same one that applies to any GH-axis therapy. Start from a baseline IGF-1, establish that a GHRH analog alone moves that number into range over 90 days, and add a secretagogue only under a prescriber working from your labs. A provider that skips baseline IGF-1 is the red flag, whether the vial holds one peptide or two.
Ipamorelin is almost always used alongside a GHRH analog, and both belong on a protocol built from a baseline IGF-1. SystemLabs tests IGF-1 before prescribing and formulates CJC-1295 and ipamorelin stacks on clinical indication, so the second peptide is added on evidence rather than by default.
Frequently Asked Questions
What is ipamorelin used for?
Ipamorelin is a growth hormone secretagogue used to stimulate a pulse of the body's own GH, usually as part of a stack with a GHRH analog like sermorelin or CJC-1295 rather than alone. Its only published human efficacy trial tested it for postoperative ileus and missed its endpoint [3]. The body composition and recovery uses it is now sold for have not been tested in a published human trial.
How is ipamorelin different from sermorelin?
They act on different receptors. Sermorelin is a GHRH analog working through the GHRH receptor, while ipamorelin is a secretagogue working through the ghrelin receptor [1]. Because the pathways are separate, the two are often combined: GHRH plus a secretagogue produced a GH response well above the sum of each alone in humans [2].
Does ipamorelin raise cortisol?
The selectivity data says it does not, but that data is from swine and rats, not humans. In the foundational study, ipamorelin did not raise ACTH or cortisol above GHRH-stimulation levels even at more than 200 times its GH ED50, while GHRP-6 and GHRP-2 did raise both [1]. Treat the cortisol advantage as strongly suggested by animal data rather than proven in people.
Is ipamorelin FDA approved?
No. FDA states there are no approved products containing ipamorelin in any form, and lists ipamorelin acetate among bulk substances flagged as a safety risk for compounding [5]. An FDA advisory committee voted 0 in favor and 12 against permitting it for compounding in October 2024 [4].
Can you take ipamorelin by itself?
You can, but it is rarely done on a considered protocol. Alone it is a single-pathway stimulus. The evidence that makes stacking attractive is the supra-additive GH response when a GHRH analog and a secretagogue are combined [2], which a solo ipamorelin protocol leaves unused.
Is ipamorelin banned in sport?
Yes. The 2026 WADA Prohibited List names ipamorelin explicitly under section S2.2.4, prohibited at all times in and out of competition, alongside other growth hormone secretagogues [6].
References
- Ipamorelin, the first selective growth hormone secretagogue European Journal of Endocrinology, 1998. PMID: 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/
- Growth hormone (GH) secretion in active acromegaly after the combined administration of GH-releasing hormone and GH-releasing peptide-6 Journal of Clinical Endocrinology & Metabolism, 1994. PMID: 8045963. https://pubmed.ncbi.nlm.nih.gov/8045963/
- Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients International Journal of Colorectal Disease, 2014. PMID: 25331030. https://pubmed.ncbi.nlm.nih.gov/25331030/
- Summary minutes of the Pharmacy Compounding Advisory Committee meeting, October 29, 2024 FDA Advisory Committee, 2024. PCAC summary minutes. https://www.fda.gov/media/185412/download
- Certain bulk drug substances for use in compounding that may present significant safety risks FDA.gov, Human Drug Compounding, 2026. Content current as of 04/22/2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- The 2026 Prohibited List: International Standard, section S2.2.4 growth hormone releasing factors World Anti-Doping Agency, 2026. WADA 2026 Prohibited List. https://www.wada-ama.org/en/resources/2026-prohibited-list
